Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag.
UniProt ID:
P29965
Concentration:
0.1mg/ml after reconstitution.
Formulation:
Lyophilized. Contains PBS.
Purity:
≥95% (SDS-PAGE)
Purity Detail:
Purified by Multi-Step Chromatography.
Endotoxin Content:
<0.1EU/µg purified protein (LAL test; Associates of Cape Cod).
Specificity:
Binds to human CD40.
Applications:
ELISA
Application Notes:
ELISA: binds to CD40 receptor at 1-10 ng/ml.
Reconstitution:
Reconstitute each tube with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein.
Shipping:
Shipped on Blue Ice
Long Term Storage:
-20°C
Use/Stability:
Stable for at least 6 months after receipt when stored at -20°C.
Handling:
Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
Technical Info/Product Notes:
Historical data has shown that CD40L stimulates growth of B cells. The activity of rhsCD40L increases 1'000-fold (stimulation in the ng/ml range) in the presence of cross-linking enhancer (see Set Prod. No. ALX-850-064). For stimulation of mouse cells via CD40 use CD40L, Soluble (mouse) (recombinant) (Prod. No. ALX-522-070 or ALX-850-075).
FLAG is a registered trademark of Sigma-Aldrich Co.
Regulatory Status:
RUO - Research Use Only
SDS-PAGE Analysis of CD40L (soluble) (human), (recombinant). Lane 1: MW Marker, Lane 2: 1 µg.
Schematic structure of human CD40L (peptide, aa. 116 to 261).
Figure 2: Stimulation of B cells by CD40L, Soluble (human) (rec.). Dose dependent costimulation of CD19+ cells by CD40L in the presence of 10ng/ml of IL-4 and of 2µg/ml anti-µ antibodies. Note that in the presence of enhancer (Prod. No. ALX-804-034), the activity of CD40L is increased >1’000 fold.Method: CD19+ cells were incubated in 96-well plates (105 cells/well in 100µl RPMI supplemented with 10% FCS) for 72 hours in the presence of 10ng/ml IL-4, 2µg/ml of goat anti-human µ chain antibody and with the indicated concentration of CD40L in the presence and absence of 1µg/ml enhancer (Prod. No. ALX-804-034). Cells were pulsed for an additional 6 hours with [3H]thymidine (1µCi/well) and harvested. [3H]thymidine incorporation was monitored by liquid scintillation counting."
Please mouse over
Product Literature References
BTK inhibition limits B-cell–T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy: R. Li, et al.; Acta Neuropathol. 143, 505 (2022), Abstract;
Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib: L. Rijvers, et al.; JCI Insight 7, e160909 (2022), Abstract;
Stage-Specific Non-Coding RNA Expression Patterns during In Vitro Human B Cell Differentiation into Antibody Secreting Plasma Cells: R.C. Tschumper, et al.; Noncoding RNA 8, 15 (2022), Abstract;
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy: H. Reimann, et al.; J. Immunother. Cancer 9, 2605 (2021), Abstract;
Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia: C. Schleiss, et al.; Leukemia 35, 1463 (2021), Abstract; Full Text
BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo: C. Schleiss, et al.; Sci. Rep. 9, 701 (2020), Abstract; Full Text
PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway: X. Wang, et al.; Mol. Immunol. 109, 20 (2019), Abstract;
Artesunate shows potent anti-tumor activity in B-cell lymphoma: T. K. Vatsveen, et al.; J. Hematol. Oncol. 11, 23 (2018), Abstract; Full Text
In vitro antineoplastic effects of auranofin in canine lymphoma cells: H. Zhang, et al.; BMC Cancer 18, 522 (2018), Abstract; Full Text
Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis: H. Masuda, et al.; J. Neuroimmunol. 316, 117 (2018), Abstract;
B-cell activation with CD40L or CpG measures the function of B-cell subsets and identifies specific defects in immunodeficient patients: E. Marasco, et al.; Eur. J. Immunol. 47, 131 (2017), Application(s): Human PBMC culture, Abstract; Full Text
CD40 signaling in Graves' disease is mediated through canonical and non-canonical thyroidal NF-κB activation: H.J. Lee, et al.; Endocrinology 158, 410 (2017), Abstract;
Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection: E.A. Miller, et al.; AIDS 29, 1287 (2015), Abstract; Full Text
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein: C. Jochems, et al.; Cancer Immunol. Immunother. 63, 161 (2014), Application(s): Stimulation of dendritic cells, Abstract;
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine: D.H. Hamilton, et al.; Oncotarget 4, 1777 (2013), Application(s): Stimulation of dendritic cells, Abstract; Full Text
Suppression by Δ9-tetrahydrocannabinol of the Primary Immunoglobulin M Response by Human Peripheral Blood B cells is Associated with Impaired STAT3 Activation: T. Ngaotepprutaram, et al.; Toxicology 310, 84 (2013), Application(s): Flow Cytometry, Abstract; Full Text
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role: J. Huang, et al.; Blood 120, 3030 (2012), Application(s): Cell Culture, Abstract; Full Text
Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function: J. Dannull, et al.; Blood 119, 3113 (2012), Application(s): Intracellular calcium release in human monocyte derived dendritic cells with Tecan Infinite plate reader, Abstract; Full Text
Targeting HIV-1 Envelope Glycoprotein Trimers to B Cells by Using APRIL Improves Antibody Responses: M. Melchers, et al.; J. Virol. 86, 2488 (2012), Application(s): Cell Culture, Abstract; Full Text
The death domain kinase RIP1 links the immunoregulatory CD40 receptor to apoptotic signaling in carcinomas: P. G. Knox, et al.; J. Cell Biol. 192, 391 (2011), Abstract; Full Text
Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand: E.H. Humphreys, et al.; PLoS One 5, e14037 (2010), Abstract; Full Text
Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas: L. Vardouli, et al.; Cancer Gene Ther. 16, 848 (2009), Application(s): Cell Culture, Abstract;
C4b Binding Protein Binds to CD154 Preventing CD40 Mediated Cholangiocyte Apoptosis: A Novel Link between Complement and Epithelial Cell Survival: K.T. Williams, et al.; PLoS ONE 2, e159 (2007), Application(s): Cell Culture, Abstract; Full Text
Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-kappaB Mutations or Activation of the CD30, CD40, and RANK Receptors: B. Zheng, et al.; Clin. Cancer Res. 10, 3207 (2004), Abstract;
HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection: S. Swingler, et al.; Nature 424, 213 (2003), Abstract; Full Text
Platelet-Activating Factor Mediates CD40-Dependent Angiogenesis and Endothelial-Smooth Muscle Cell Interaction: S. Russo, et al.; J. Immunol. 171, 5489 (2003), Abstract;
Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells: N. Harada, et al.; BBRC 299, 488 (2002), Abstract;
Suppression of IL-12 Production by Soluble CD40 Ligand: Evidence for Involvement of the p44/42 Mitogen-Activated Protein Kinase Pathway: M. Wittmann, et al.; J. Immunol. 168, 3793 (2002), Abstract;
Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling: S.P. Atamas, et al.; J. Immunol. 168, 1139 (2002), Abstract;
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines: P. Fiumara, et al.; Blood 98, 2784 (2001), Abstract; Full Text
Histamine polarizes human dendritic cells into Th2 cell-promoting effector dendritic cells: G. Caron, et al.; J. Immunol. 167, 3682 (2001), Abstract;
CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway: J. Tan, et al.; J. Biol. Chem. 275, 37224 (2000), Abstract; Full Text
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity: P. Schneider, et al.; J. Exp. Med. 187, 12051 (1998), Abstract; Full Text
Ligand plus enhancer for improved stability and enhanced immune activation.
Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag., ≥95% (SDS-PAGE)., FUNC | Print as PDF
Produced in HEK 293 cells. The extracellular domain of mouse CD40L (CD154) (aa 115-260) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag., ≥90% (SDS-PAGE), ELISA | Print as PDF
Produced in HEK 293 cells. The extracellular domain of mouse CD40L (CD154) (aa 115-260) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag., ≥90% (SDS-PAGE)., ELISA, FUNC | Print as PDF
High activity, high purity CD40L protein for co-stimulatory activation of an immune response
Produced in CHO cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥90% (SDS-PAGE) | Print as PDF
High activity, high purity CD40L protein for co-stimulatory activation of an immune response
Produced in CHO cells. The extracellular domain of mouse CD40L (CD154) (aa 115-260) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥95% (SDS-PAGE) | Print as PDF
